BSH 2017: Management of Asymptomatic Follicular Lymphoma
The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.
The old mantra is that advanced follicular lymphoma (FL) cannot be cured and treatment does not influence survival but this is no longer the case – follicular lymphoma… read more.
Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.
Scientists in Germany have successfully reprogrammed liver cells, turning them into pancreas progenitor cells by altering a single gene. The team behind the breakthrough, at the Max Delbrück… read more.
Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.
Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.
Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.
High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.
Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…
Dr Andrei Shustov (University of Washington School of Medicine, Seattle, USA) summarises the advances in T-Cell lymphoma therapy at ASH 2016, including long term data in PTCL and ALCL…. read more.
Professor Mohamad Mohty (Paris), Professor Sagar Lonial (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.
Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.
Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.